David Demanse

2.4k total citations · 2 hit papers
41 papers, 1.8k citations indexed

About

David Demanse is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Demanse has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in David Demanse's work include PI3K/AKT/mTOR signaling in cancer (15 papers), Advanced Breast Cancer Therapies (14 papers) and Cancer Treatment and Pharmacology (12 papers). David Demanse is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (15 papers), Advanced Breast Cancer Therapies (14 papers) and Cancer Treatment and Pharmacology (12 papers). David Demanse collaborates with scholars based in Switzerland, United States and Spain. David Demanse's co-authors include José Baselga, Jordi Rodón, Howard A. Burris, Malte Peters, Qinhua Ru, Stefan S. De Buck, Michael Goldbrunner, Diana C. Birle, Johanna C. Bendell and Jaap Verweij and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

David Demanse

40 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

2011 550 citations Johanna C. Bendell, Jordi Rodón et al. Journal of Clinical Oncology profile →
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Demanse Switzerland	16	1.2k	699	630	363	335	41	1.8k
Maja J.A. de Jonge Netherlands	19	865 0.7×	848 1.2×	420 0.7×	170 0.5×	259 0.8×	40	1.6k
Brett E. Houk United States	17	950 0.8×	606 0.9×	711 1.1×	163 0.4×	247 0.7×	49	1.6k
Katharine Hazell Switzerland	12	904 0.7×	491 0.7×	423 0.7×	202 0.6×	196 0.6×	19	1.3k
Jean Powers Canada	17	561 0.5×	556 0.8×	383 0.6×	270 0.7×	154 0.5×	32	1.3k
Maria Luisa Veronese United States	18	969 0.8×	678 1.0×	340 0.5×	136 0.4×	190 0.6×	35	1.8k
Céline Callens France	27	1.0k 0.9×	670 1.0×	480 0.8×	153 0.4×	740 2.2×	83	2.2k
G. Veerman Netherlands	20	635 0.5×	1.1k 1.6×	730 1.2×	142 0.4×	236 0.7×	52	1.9k
Celine Wilke United States	8	777 0.6×	960 1.4×	905 1.4×	406 1.1×	639 1.9×	20	2.2k
Howard Fingert United States	23	765 0.6×	1.1k 1.5×	220 0.3×	134 0.4×	209 0.6×	47	1.9k
Ioannis A. Voutsadakis Canada	27	914 0.8×	1.2k 1.8×	474 0.8×	91 0.3×	639 1.9×	161	2.3k

Countries citing papers authored by David Demanse

Since Specialization

Citations

This map shows the geographic impact of David Demanse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Demanse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Demanse more than expected).

Fields of papers citing papers by David Demanse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Demanse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Demanse. The network helps show where David Demanse may publish in the future.

Co-authorship network of co-authors of David Demanse

This figure shows the co-authorship network connecting the top 25 collaborators of David Demanse. A scholar is included among the top collaborators of David Demanse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Demanse. David Demanse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Solomon, Benjamin, Daniel S.W. Tan, Gilberto de Castro, et al.. (2025). The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Research Communications. 5(4). 632–646. 1 indexed citations

Saxer, Franziska, David Demanse, Alan Brett, et al.. (2024). Prognostic value of B-score for predicting joint replacement in the context of osteoarthritis phenotypes: Data from the osteoarthritis initiative. SHILAP Revista de lepidopterología. 6(2). 100458–100458. 3 indexed citations

Rodón, Jordi, David Demanse, Hope S. Rugo, et al.. (2024). A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. Breast Cancer Research. 26(1). 36–36. 8 indexed citations

Paz‐Ares, Luis, Yasushi Goto, Wan‐Teck Lim, et al.. (2024). Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer. 189. 107451–107451. 22 indexed citations

Razak, Albiruni Ryan Abdul, Hung‐Ming Wang, Jang‐Yang Chang, et al.. (2023). A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted Oncology. 18(6). 853–868. 10 indexed citations

Lascio, Elena Di, et al.. (2023). Association of digital measures and self-reported fatigue: a remote observational study in healthy participants and participants with chronic inflammatory rheumatic disease. Frontiers in Digital Health. 5. 1099456–1099456. 3 indexed citations

Demanse, David, Franziska Saxer, P Lustenberger, et al.. (2022). Unsupervised machine-learning algorithms for the identification of clinical phenotypes in the osteoarthritis initiative database. Seminars in Arthritis and Rheumatism. 58. 152140–152140. 17 indexed citations

Wolf, Jennifer Moriatis, Henk Groen, Daniel S.W. Tan, et al.. (2022). 986P Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study. Annals of Oncology. 33. S1003–S1003. 1 indexed citations

Rodón, Jordi, David Demanse, Hope S. Rugo, et al.. (2021). 96MO A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1. Annals of Oncology. 32. S64–S64. 2 indexed citations

10.

Luen, Stephen J., Rebecca Asher, Chee Khoon Lee, et al.. (2020). Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology. 31(10). 1359–1365. 4 indexed citations

11.

Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →

12.

Rodón, Jordi, José Alejandro Pérez Fidalgo, Ian E. Krop, et al.. (2018). Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 82(2). 285–298. 40 indexed citations

13.

Juric, Dejan, Filip Jankú, Jordi Rodón, et al.. (2018). Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer. JAMA Oncology. 5(2). e184475–e184475. 186 indexed citations

14.

Bédard, Philippe L., Josep Tabernero, Filip Jankú, et al.. (2014). A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research. 21(4). 730–738. 257 indexed citations

15.

Juric, Dejan, Martin Schüler, J. Schellens, et al.. (2014). Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast). Annals of Oncology. 25. iv150–iv150. 7 indexed citations

16.

Juric, Dejan, Martin Schüler, Jordan Berlin, et al.. (2013). Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study. Cancer Research. 73(24_Supplement). P2–16. 12 indexed citations

17.

Krop, Ian E., Cristina Saura, Jordi Rodón, et al.. (2012). A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.. Journal of Clinical Oncology. 30(15_suppl). 508–508. 28 indexed citations

18.

Burris, H. A., Jordi Rodón, A.R. Abdul Razak, et al.. (2011). Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.. Journal of Clinical Oncology. 29(15_suppl). 3043–3043. 19 indexed citations

19.

Rouprêt, Morgan, Vincent Hupertan, Éva Compérat, et al.. (2009). Cross‐cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy. British Journal of Urology. 104(6). 813–818. 13 indexed citations

20.

Gratacap-Cavallier, B., et al.. (2003). Are waterborne astrovirus implicated in acute digestive morbidity (E.MI.R.A. study)?. Journal of Clinical Virology. 27(1). 74–82. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact